UGT1A5 (F-19): sc-27429



The Power to Question

BACKGROUND

Glucuronidation, an important bile acid detoxification pathway, is catalyzed by enzymes belonging to the UDP-glucuronosyltransferase (UGT) superfamily. UGT genes are classified into the UGT1A and UGT2B subfamilies. Although each subfamily and each isoform shows tissue-specific patterns of distribution, the underlying mechanisms for this tissue specificity have not been fully elucidated. The human UDP-glucuronosyltransferase 1 (UGT1) locus encodes at least ten UGT1A proteins (UGT1A1-UGT1A10) that play a prominent role in drug and xenobiotic metabolism. Research indicates that nuclear receptors such as pregnane X receptor (PXR), constitutive androstane receptor (CAR) and peroxisome proliferator-activated receptor (PPAR) can regulate UGTs, which may contribute to the tissue-specific expression pattern of UGTs. Deficiency in the expression and/or activity of UGTs may lead to genetic and acquired diseases such as Crigler-Najjar syndrome and Gilbert syndrome. Based on their ability to catalyze the glucuronidation of xenobiotics and endobiotics, UGTs play a critical role in hormonal homeostasis, energy metabolism, bilirubin clearance and xenobiotic detoxification.

REFERENCES

- Moghrabi, N., et al. 1992. Chromosomal assignment of human phenol and bilirubin UDP-glucuronosyltransferase genes (UGT1A-subfamily). Ann. Hum. Genet. 56: 81-91.
- Owens, I.S., et al. 1996. The novel UGT1 gene complex links bilirubin, xenobiotics and therapeutic drug metabolism by encoding UDP-glucuronosyltransferase isozymes with a common carboxyl terminus. J. Pharmacokinet. Biopharm. 24: 491-508.
- Ciotti, M., et al. 1997. Genetic defects at the UGT1 locus associated with Crigler-Najjar type I disease, including a prenatal diagnosis. Am. J. Med. Genet. 68:173-178.
- Strassburg, C.P., et al. 1997. Differential downregulation of the UDP-glucuronosyltransferase 1A locus is an early event in human liver and biliary cancer. Cancer Res. 57:2979-2985.
- Thomas, S.S., et al. 2006. Genetic variability, haplotypes and htSNPs for exons 1 at the human UGT1A locus. Hum. Mutat. 27: 717.
- Han, J.Y., et al. 2006. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J. Clin. Oncol. 24: 2237-2244.

SOURCE

UGT1A5 (F-19) is an affinity purified goat polyclonal antibody raised against a peptide mapping near the N-terminus of UGT1A5 of rat origin.

PRODUCT

Each vial contains 200 μg lgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-27429 P, (100 μ g peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

APPLICATIONS

UGT1A5 (F-19) is recommended for detection of UGT1A5 of rat origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use donkey anti-goat IgG-FITC: sc-2024 (dilution range: 1:100-1:400) or donkey anti-goat IgG-TR: sc-2783 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

SELECT PRODUCT CITATIONS

 Bolling, B.W., et al. 2011. Microsomal quercetin glucuronidation in rat small intestine depends on age and segment. Drug Metab. Dispos. 39: 1406-1414.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.



Try **UGT1A** (**B-4**): **sc-271268**, our highly recommended monoclonal alternative to UGT1A5 (F-19). Also, for AC, HRP, FITC, PE, Alexa Fluor[®] 488 and Alexa Fluor[®] 647 conjugates, see **UGT1A** (**B-4**): **sc-271268**.

Santa Cruz Biotechnology, Inc. 1.800.457.3801 831.457.3801 Fax 831.457.3801 Europe +00800 4573 8000 49 6221 4503 0 www.scbt.com